NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis $0.90 -0.05 (-5.26%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$0.86▼$0.9950-Day Range$0.71▼$4.1252-Week Range$0.68▼$153.30Volume274,168 shsAverage Volume1.51 million shsMarket Capitalization$1.12 millionP/E RatioN/ADividend YieldN/APrice Target$87.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media ZyVersa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9,622.2% Upside$87.50 Price TargetShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($138.81) to ($10.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 stars 3.5 Analyst's Opinion Consensus RatingZyVersa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $87.50, ZyVersa Therapeutics has a forecasted upside of 9,622.2% from its current price of $0.90.Amount of Analyst CoverageZyVersa Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.36% of the float of ZyVersa Therapeutics has been sold short.Short Interest Ratio / Days to CoverZyVersa Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ZyVersa Therapeutics has recently increased by 152.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZyVersa Therapeutics does not currently pay a dividend.Dividend GrowthZyVersa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVSA. Previous Next 3.1 News and Social Media Coverage News SentimentZyVersa Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ZyVersa Therapeutics this week, compared to 1 article on an average week.Search Interest12 people have searched for ZVSA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows14 people have added ZyVersa Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZyVersa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.92% of the stock of ZyVersa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 36.69% of the stock of ZyVersa Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ZyVersa Therapeutics are expected to grow in the coming year, from ($138.81) to ($10.77) per share.Price to Book Value per Share RatioZyVersa Therapeutics has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.Read More ZVSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVSA Stock News HeadlinesDecember 29, 2023 | americanbankingnews.comShort Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Rises By 152.2%December 22, 2023 | benzinga.comThis Biotech Is Targeting Indications Worth $70 BillionDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionDecember 18, 2023 | finance.yahoo.comZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”December 16, 2023 | markets.businessinsider.comBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Clinical Trials and Solid Financial PositionDecember 16, 2023 | msn.comZyVersa Therapeutics (ZVSA) Price Target Increased by 860.00% to 24.48December 14, 2023 | finance.yahoo.comZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200December 14, 2023 | finance.yahoo.comZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200December 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)December 8, 2023 | uk.finance.yahoo.comZyVersa Therapeutics, Inc. (ZVSA)December 7, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 DiabetesDecember 7, 2023 | marketwatch.comZyVersa Therapeutics Shares Slide Premarket After OfferingDecember 7, 2023 | markets.businessinsider.comWhy Is Cerevel Therapeutics (CERE) Stock Up 12% Today?December 7, 2023 | benzinga.comWhy ZyVersa Therapeutics Shares Are Down 40%December 7, 2023 | msn.comWhy Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?December 6, 2023 | finance.yahoo.comZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public OfferingDecember 6, 2023 | markets.businessinsider.comZyVersa Jumps 32% After AIM2 And NLRP3 Inflammasomes Promote Atherosclerosis In DiabetesDecember 6, 2023 | investorplace.comWhy Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today?December 6, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome PathwaysNovember 30, 2023 | finance.yahoo.comZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common StockNovember 14, 2023 | finance.yahoo.comZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial ResultsNovember 9, 2023 | morningstar.comZyVersa Therapeutics Inc ZVSANovember 9, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal ModelNovember 6, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 ActivationNovember 1, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing NeuroprotectionOctober 25, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart DiseaseOctober 18, 2023 | finance.yahoo.comZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney FunctionSee More Headlines Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZVSA CUSIPN/A CIK1859007 Webwww.zyversa.com Phone754-231-1688FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$87.50 High Stock Price Target$87.50 Low Stock Price Target$87.50 Potential Upside/Downside+9,622.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-131.47% Return on Assets-104.25% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$386.50 per share Price / Book0.00Miscellaneous Outstanding Shares1,245,000Free Float1,184,000Market Cap$1.12 million OptionableNot Optionable Beta0.27 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Stephen C. Glover (Age 63)Co-Founder, Chairman, CEO & President Comp: $450.5kMr. Peter Wolfe (Age 55)CFO & Secretary Comp: $275kMs. Karen A. Cashmere (Age 71)Chief Commercial Officer Comp: $300kMs. Melda Uzbil O'connellSenior Vice President of Corporate DevelopmentDr. Pablo A. Guzman FACC (Age 73)M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board Key CompetitorsAvalo TherapeuticsNASDAQ:AVTXAltamira TherapeuticsNASDAQ:CYTOAditxtNASDAQ:ADTXChina SXT PharmaceuticalsNASDAQ:SXTCGRI BioNASDAQ:GRIView All CompetitorsInstitutional OwnershipWalleye Capital LLCBought 980,568 shares on 11/21/2023Ownership: 3.174%View All Institutional Transactions ZVSA Stock Analysis - Frequently Asked Questions Should I buy or sell ZyVersa Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZyVersa Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVSA shares. View ZVSA analyst ratings or view top-rated stocks. What is ZyVersa Therapeutics' stock price target for 2024? 1 analysts have issued 1 year target prices for ZyVersa Therapeutics' shares. Their ZVSA share price targets range from $87.50 to $87.50. On average, they expect the company's stock price to reach $87.50 in the next twelve months. This suggests a possible upside of 9,622.2% from the stock's current price. View analysts price targets for ZVSA or view top-rated stocks among Wall Street analysts. How have ZVSA shares performed in 2023? ZyVersa Therapeutics' stock was trading at $54.95 at the beginning of 2023. Since then, ZVSA stock has decreased by 98.4% and is now trading at $0.90. View the best growth stocks for 2023 here. When is ZyVersa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ZVSA earnings forecast. How were ZyVersa Therapeutics' earnings last quarter? ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its earnings results on Tuesday, November, 14th. The company reported ($3.15) earnings per share for the quarter, beating the consensus estimate of ($5.60) by $2.45. When did ZyVersa Therapeutics' stock split? ZyVersa Therapeutics's stock reverse split on the morning of Tuesday, December 5th 2023. The 1-35 reverse split was announced on Tuesday, December 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVSA) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.